Navigation Links
Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses
Date:10/22/2008

Shareholders' Meeting to be Held on November 18, 2008

WITTEN, Germany, October 22 /PRNewswire-FirstCall/ -- Sangui BioTech International, Inc., published its financial statements for its fiscal year ended June 30, 2008, on October 21. According to the report on form 10-KSB as filed with the SEC the company yielded sales of its cosmetics and wound management products in the amount of approximately USD 207,000 a decrease of 44% as compared with sales revenues of approximately USD 372,000 in the previous year. The decrease is attributable to the company's focus on product development (new cosmetics series, new surgical application of Chitoskin wound pads) and a lower return on marketing efforts with respect to cosmetic products. This also entailed higher research and development cost as well as an increase in General and administrative expenses.

The company reports a net loss for the year of approximately USD 854,000 (2007 net loss: approximately USD 721,000). The resulting accumulated deficit amounts to approximately USD 23.3 million. Total shareholders' deficit as of June 30, 2006 stands at approximately USD 1.1 million. Net cash used in operating activities of approximately USD 1.1 million was offset by cash inflows from financing activities (net of effects of exchange rates) in the amount of approximately USD 1.4 million.

Operations in the 2008 financial year were financed by investments from several European investors in the amount of approximately USD 994,000. In accordance with US-GAAP the amount is shown as foreign currency translation adjustments in the profit-and-loss statement.

The company invites its shareholders to attend the General Meeting of Shareholders on November 18, 2008 on the premises of the Forschungs- und Entwicklungszentrum in Witten, Germany.

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. (htp://www.pinksheets.com: SGBI)

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:

Joachim Fleing

Phone: +49-160-741-27-17

Fax: +49-2302-915-191

e-mail: fleing@sangui.de


'/>"/>
SOURCE Sangui Bio Tech International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangui Partnership Enters a New Phase:
2. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
3. Investors Acquire Share in Sangui BioTech GmbH
4. Sangui BioTech International, Inc. Files Remaining Reports
5. Sangui Bio Tech International Inc. Shareholders Meeting Delayed to Include FY 2008 Report
6. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
9. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
10. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
11. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand ... 4.6 percent through 2020 to $7.2 billion.  This ... and beverages, cleaning products, biofuel production, animal feed, ... biotechnology, diagnostics, and biocatalysts). Food and beverages will ... driven by increasing consumption of products containing enzymes ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):